Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia.
Oxcarbazepine, a new drug with antineuralgic properties has been evaluated in a long-term follow-up of 6 patients (2 males, 4 females; aged 42-77 years; mean 61 years), previously reported on with trigeminal neuralgia. Daily oral oxcarbazepine dose correlated significantly with both total oxcarbazepine (r = 0.851) and 10-OH-carbazepine (r = 0.958) serum concentrations. Mean percent free oxcarbazepine and 10-OH-carbazepine was 41 and 61% respectively and there was no significant difference in binding between male and female patients. Free serum concentrations of oxcarbazepine and 10-OH-carbazepine correlated significantly with total serum oxcarbazepine and 10-OH-carbazepine respectively, indicating that binding capacity of both are essentially constant within the respective ranges of 0.2-11.4 mumol.l-1 and 20-150 mumol.l-1 observed in the present study.
Patsalos
P N
PN
University Department of Clinical Neurology, National Hospital, London, UK.
Elyas
A A
AA
Zakrzewska
J M
JM
D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000378:metabolism*; D002220:Carbamazepine / Q000031:analogs & derivatives* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000078330:Oxcarbazepine; D011485:Protein Binding; D014277:Trigeminal Neuralgia / Q000378:metabolism*
C039775:10,11-dihydro-10-hydroxycarbamazepine; D001798:Blood Proteins; D002220:Carbamazepine; D000078330:Oxcarbazepine